Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Scienture Holdings, Inc. has secured $11 million in non-dilutive debt financing through promissory notes to support the commercialization of its FDA-approved products, Arbli™ for hypertension and REZENOPY™ for opioid overdose treatment, as well as to advance its diverse R&D pipeline. The financing aims to strengthen Scienture's capital position and…